Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

被引：0
|
作者：
Herbert H. Loong
Carlos K. H. Wong
Linda K. S. Leung
Catherine P. K. Chan
Andrea Chang
Zheng-Yi Zhou
Jipan Xie
Meaghan Gibbs
机构：
[1] The Chinese University of Hong Kong,Department of Clinical Oncology
[2] The University of Hong Kong,Department of Family Medicine and Primary Care
[3] Novartis Pharmaceuticals Corporation,undefined
[4] Analysis Group,undefined
[5] Inc,undefined
[6] Analysis Group,undefined
[7] Inc,undefined
[8] Novartis Pharmaceuticals Corporation,undefined
来源：
Cost Effectiveness and Resource Allocation | / 18卷
关键词：
Advanced non-small cell lung cancer; Anaplastic lymphoma kinase-positive; Ceritinib; cost-effectiveness; Hong kong;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Loong, Herbert H.
    Wong, Carlos K. H.
    Leung, Linda K. S.
    Chan, Catherine P. K.
    Chang, Andrea
    Zhou, Zheng-Yi
    Xie, Jipan
    Gibbs, Meaghan
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
  • [2] Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong
    Loong, H. H.
    Wong, C. K. H.
    Leung, L. K. S.
    Chan, C. P. K.
    Chang, A.
    Gibbs, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer in Canada
    Hurry, Manjusha
    Zhou, Zheng-Yi
    Zhang, Jie
    Zhang, Chenxue
    Fan, Liangyi
    Rebeira, Mayvis
    Xie, Jipan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 936 - 944
  • [4] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY TREATED PATIENTS WITH CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN CANADA
    Zhou, Z.
    Hurry, M.
    Zhang, J.
    Fan, L.
    Zhang, C.
    Xie, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A462 - A462
  • [5] COST-EFFECTIVENESS ANALYSIS OF CERITINIB IN PATIENTS PREVIOUSLY TREATED WITH CRIZOTINIB AND CHEMOTHERAPY IN ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN UNITED STATES
    Zhang, Y.
    Shao, Y.
    Shi, L.
    [J]. VALUE IN HEALTH, 2020, 23 : S32 - S32
  • [6] Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States
    Zhou, Zheng-Yi
    Mutebi, Alex
    Han, Simeng
    Bensimon, Arielle G.
    Ricculli, Marie Louise
    Xie, Jipan
    Dalal, Anand
    Culver, Ken
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (06) : 577 - 586
  • [7] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Xie, J.
    Knoll, S.
    Slowley, A.
    Bensimon, A.
    Vieira, J.
    Chilcott, J.
    Paisley, S.
    Zhou, Z.
    [J]. VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [8] COST-EFFECTIVENESS OF CERITINIB IN THE TREATMENT OF PREVIOUSLY TREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Zhou, Z.
    Zhang, J.
    Fan, L.
    Zhang, C.
    Xie, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A455 - A456
  • [9] Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
    Liu, Maobai
    Zhang, Longfeng
    Huang, Qishu
    Li, Na
    Zheng, Bin
    Cai, Hongfu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9195 - 9201
  • [10] COST-EFFECTIVENESS OF CRIZOTINIB, CERITINIB, AND ALECTINIB AS FIRST-LINE TREATMENTS FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) METASTATIC NON-SMALL CELL LUNG CANCER
    Xuan, S.
    Ma, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S32 - S33
12345